Genetic variation in IL28B and spontaneous clearance of hepatitis C virus


Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with estimates of 4 million HCV-infected individuals in the United States and 170 million worldwide1. Most (70–80%) HCV infections persist and about 30% of individuals with persistent infection develop chronic liver disease, including cirrhosis and hepatocellular carcinoma2. Epidemiological, viral and host factors have been associated with the differences in HCV clearance or persistence, and studies have demonstrated that a strong host immune response against HCV favours viral clearance3,4. Thus, variation in genes involved in the immune response may contribute to the ability to clear the virus. In a recent genome-wide association study, a single nucleotide polymorphism (rs12979860) 3 kilobases upstream of the IL28B gene, which encodes the type III interferon IFN-λ3, was shown to associate strongly with more than a twofold difference in response to HCV drug treatment5. To determine the potential effect of rs12979860 variation on outcome to HCV infection in a natural history setting, we genotyped this variant in HCV cohorts comprised of individuals who spontaneously cleared the virus (n = 388) or had persistent infection (n = 620). We show that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry. To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Percentage of HCV clearance by rs12979860 genotype.
Figure 2: Sampling locations, allele frequencies and degree of regional differentiation of the rs12979860 C allele.

Change history

  • 08 October 2009

    Two sentences were removed from the text on 8 October 2009.


  1. 1

    Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47, 1–39 (1998)

  2. 2

    Seeff, L. B. Natural history of chronic hepatitis C. Hepatology 36 (suppl. 1). S35–S46 (2002)

  3. 3

    Cooper, S. et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439–449 (1999)

  4. 4

    Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215–229 (2005)

  5. 5

    Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature advance online publication 10.1038/nature08309 (16 August 2009)

  6. 6

    Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340, 1228–1233 (1999)

  7. 7

    Thomas, D. L. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J. Am. Med. Assoc. 284, 450–456 (2000)

  8. 8

    Thio, C. L. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver Dis. 12, 713–726 (2008)

  9. 9

    Thio, C. L., Thomas, D. L. & Carrington, M. Chronic viral hepatitis and the human genome. Hepatology 31, 819–827 (2000)

  10. 10

    McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580–593 (2009)

  11. 11

    Lindsay, K. L. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395–403 (2001)

  12. 12

    Zeuzem, S. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666–1672 (2000)

  13. 13

    Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S. & Thomas, D. L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29, 908–914 (1999)

  14. 14

    Goldstein, D. B. Common genetic variation and human traits. N. Engl. J. Med. 360, 1696–1698 (2009)

  15. 15

    Kotenko, S. V. et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4, 69–77 (2003)

  16. 16

    Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol. 4, 63–68 (2003)

  17. 17

    Marcello, T. et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887–1898 (2006)

  18. 18

    Dellgren, C., Gad, H. H., Hamming, O. J., Melchjorsen, J. & Hartmann, R. Human interferon-λ3 is a potent member of the type III interferon family. Genes Immun. 10, 125–131 (2009)

  19. 19

    Lauer, G. M. & Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 345, 41–52 (2001)

  20. 20

    Donnelly, R. P., Sheikh, F., Kotenko, S. V. & Dickensheets, H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. 76, 314–321 (2004)

  21. 21

    Vlahov, D. et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res. Monogr. 109, 75–100 (1991)

  22. 22

    Goedert, J. J. et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N. Engl. J. Med. 321, 1141–1148 (1989)

  23. 23

    Hilgartner, M. W. et al. Hemophilia growth and development study. Design, methods, and entry data. Am. J. Pediatr. Hematol. Oncol. 15, 208–218 (1993)

  24. 24

    Osier, M. V. et al. ALFRED: An allele frequency database for anthropology. Am. J. Phys. Anthropol. 119, 77–83 (2002)

Download references


This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract number HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This Research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This research was supported by NIH grants R01DA013324 (D.L.T.), R01DA004334 (G.D.K.), R01HL076902 (M.P.B.), R01DK60590 (H.R.R.) and R01HD41224 (S.M.D.). S.I.K. is a Wellcome Trust Senior Clinical Fellow.

Author Contributions D.L.T., C.L.T., J.G.M., D.B.G. and M.C. designed the study. M.C. directed the study. M.P.M. performed the genotyping. M.P.M. and M.C. wrote the manuscript, with major edits by D.L.T., C.L.T. and D.B.G. The analyses were performed by Y.Q., D.G. and C.O. The samples used in the study were provided by C.L.T., J.K., K.K., S.I.K., G.A., J.J.G., G.D.K., S.M.D., H.R.R., L.H.T., M.P.B. and D.L.T. All authors contributed to preparing the final manuscript.

Author information

Correspondence to Mary Carrington.

Supplementary information

Supplementary Information

This file contains Supplementary Notes, Supplementary Tables S1-S3, Supplementary Figure S1 with Legend and a Supplementary Reference. (PDF 295 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thomas, D., Thio, C., Martin, M. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.